Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies

Documenti analoghi

• Baseline multi‐omics signatures could predict therapeutic response to neoadjuvant anti‐PD‐1 immunochemotherapy in non‐small‐cell lung cancer
  di: Ailing Cao, et al.
  Pubblicazione: (2026)
• Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion‐driven non‐small cell lung cancer
  di: Antoine Desilets, et al.
  Pubblicazione: (2024)
• Multi‐omics molecular phenotyping reveals the potential mechanisms of chemotherapy response and resistance in small cell lung cancer
  di: Ying Cheng, et al.
  Pubblicazione: (2024)
• Single‐cell sequencing for cancer precision medicine: From mechanism discovery to diagnosis and therapeutics
  di: Yue Zhao, et al.
  Pubblicazione: (2026)
• Distinct fibroblast subpopulations associated with bone, brain or intrapulmonary metastasis in advanced non‐small‐cell lung cancer
  di: Ke Xu, et al.
  Pubblicazione: (2024)